It is worth noting that Xiangnan Guan et al. [133] recently identified androgen receptor (AR) as an essential element affecting the reactivity of prostate cancer patients to ICI therapy, and revealed the mechanism by which AR modulates antitumor immunity by regulating IFNγ activity. This evidence concerns the gene IFNG and prostate carcinoma.